Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
REGENERON PHARMACEUTICALS, INC. incurred revolving credit of $750 million with JPMorgan Chase Bank, N.A. at variable interest rate based on SOFR or alternate base rate plus applicable marg maturing December 19, 2027.
- Instrument
- revolving credit
- Principal
- $750 million
- Counterparty
- JPMorgan Chase Bank, N.A.
- Rate
- variable interest rate based on SOFR or alternate base rate plus applicable marg
- Maturity
- December 19, 2027
- Event
- incurrence
Exact text from the filing
The Credit Agreement provides for a $750 million senior unsecured five-year revolving credit facility (with a $25 million sublimit for swingline borrowings and a $50 million sublimit for letters of credit)
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
REGENERON PHARMACEUTICALS, INC. terminated Prior Credit Agreement with JPMorgan Chase Bank, N.A. valued at Prior $750 million revolving credit facility terminated (effective 2022-12-19).
- Action
- termination
- Agreement
- credit facility
- Counterparty
- JPMorgan Chase Bank, N.A.
- Value
- Prior $750 million revolving credit facility terminated
- Effective
- 2022-12-19
Exact text from the filing
On the Closing Date, in connection with the entry into the Credit Agreement as described in Item 1.01 above, the Company terminated its then-existing credit agreement, dated as of December 14, 2018, as amended prior to the Closing Date (the “ Prior Credit Agreement ”), by and among Regeneron, as a borrower and guarantor; certain subsidiaries of Regeneron party thereto as subsidiary borrowers; the lenders and issuing banks from time to time party thereto; and JPMorgan Chase Bank, N.A., as administrative agent, swingline lender, and an issuing bank.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
REGENERON PHARMACEUTICALS, INC. entered into Credit Agreement with JPMorgan Chase Bank, N.A. valued at $750 million senior unsecured five-year revolving credit facility (effective 2022-12-19).
- Action
- entry
- Agreement
- credit facility
- Counterparty
- JPMorgan Chase Bank, N.A.
- Value
- $750 million senior unsecured five-year revolving credit facility
- Effective
- 2022-12-19
Exact text from the filing
On December 19, 2022 (the “ Closing Date ”), Regeneron Pharmaceuticals, Inc. (“ Regeneron ” or the “ Company ”) entered into a credit agreement (the “ Credit Agreement ”) by and among the Company, as a borrower and guarantor; certain direct subsidiaries of the Company, as the initial subsidiary borrowers; the lenders and issuing banks from time to time party thereto; and JPMorgan Chase Bank, N.A., as administrative agent, swingline lender, and an issuing bank. The Credit Agreement provides for a $750 million senior unsecured five-year revolving credit facility
View on SEC.gov